Stockscreener 앱 받기
2.3539
8.53%
0.1839
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to "Neutral" at JPMorgan Chase & Co. - MarketBeat
H.C. Wainwright cuts Allogene stock price target to $11 from $12 - Investing.com Canada
Dell To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
JPMorgan Upgrades Allogene Therapeutics to Neutral From Underweight - marketscreener.com
HC Wainwright Issues Optimistic Outlook for ALLO Earnings - MarketBeat
JPMorgan upgrades Allogene stock rating to neutral after pullback - Investing.com
ALLO Maintained by Jefferies -- Price Target Raised to $10.00 - GuruFocus
Allogene Therapeutics Prices Large Common Stock Offering - TipRanks
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? - Yahoo Finance
ALLO Stock Slumps As $175M Secondary Offering Hits Tape - timothysykes.com
ALLO Stock Slides As $175M Equity Offering Hits Tape - StocksToTrade
[8-K] Allogene Therapeutics, Inc. Reports Material Event - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) to Sell 87.5M Shares at $2.00 - Stock Titan
Allogene Therapeutics (NASDAQ:ALLO) Shares Gap DownTime to Sell? - MarketBeat
ALLO Stock Drops As $175M Equity Raise Hits Tape - StocksToTrade
Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings - Benzinga
Jefferies raises Allogene stock price target to $10 on trial data By Investing.com - Investing.com South Africa
Traders Buy Large Volume of Put Options on Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat
Jefferies raises Allogene stock price target to $10 on trial data - Investing.com
ALLO Stock Slides As $175M Equity Raise Hits Tape - StocksToTrade
ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’ - MSN
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases - The Manila Times
Allogene publishes preclinical data for autoimmune CAR T therapy - Investing.com
Autoimmune drug candidate cleared B and T cells in lupus models - Stock Titan
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to Strong-Buy at Jefferies Financial Group - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Significant Growth in Short Interest - MarketBeat
ALLO Seeks Capital with a New Offering Below Previous Close - GuruFocus
Allogene Therapeutics Prices $175 Million Public Offering - marketscreener.com
Allogene Therapeutics Shares Slide on Up to $201.3M Public Offering - Moomoo
Allogene Therapeutics prices $175M stock offering at $2 per share - MSN
Biotech Allogene sells 87.5M shares at $2 to raise $175M - Stock Titan
Allogene prices $175 million stock offering at $2 per share By Investing.com - Investing.com South Africa
ALLO Maintained by Argus Research -- Price Target Raised to $3.8 - GuruFocus
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - Bitget
Allogene Therapeutics, Inc. Prices Public Offering of 87.5 Million Shares at $2.00 per Share - Quiver Quantitative
Allogene prices $175 million stock offering at $2 per share - Investing.com
Allogene Therapeutics announces pricing of public offering of common stock - marketscreener.com
Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock - TradingView — Track All Markets
Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com
ALLO Maintained by Citizens -- Price Target Raised to $8.00 - GuruFocus
Allogene Therapeutics plans $175 million stock offering By Investing.com - Investing.com Australia
ALLO Maintained by HC Wainwright & Co. -- Price Target Raised to $12 - GuruFocus
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study - Yahoo Finance
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Expected to Rise, Argus Analyst Says - MarketBeat
ALLO Maintained by Baird -- Price Target Raised to $9.00 - GuruFocus
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
Allogene Therapeutics Stock Soars 12% On Positive Phase 2 Data For Lymphoma Treatment - TIKR.com
H.C. Wainwright raises Allogene stock price target on trial data - Investing.com UK
H.C. Wainwright raises Allogene stock price target on trial data By Investing.com - Investing.com Australia
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Bernstein raises Allogene stock price target on trial data By Investing.com - Investing.com India
Bernstein raises Allogene stock price target on trial data - Investing.com UK
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Allogene Therapeutics (NASDAQ:ALLO) Sets New 1-Year HighHere's Why - MarketBeat
Allogene Therapeutics (ALLO) Plans $175M Stock Offering - GuruFocus
Allogene Therapeutics, Inc. Files Form 8-K Current Report with SEC on April 13, 2026 2 - Minichart
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell LymphomaSlideshow (NASDAQ:ALLO) 2026-04-14 - Seeking Alpha
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock - Bitget
1.33%
1.07%
자본화:
|
볼륨(24시간):